GLP‑1 weight‑loss drugs spark new pet treatments and post‑diet surgery demand in Brazil

Researchers in Brazil tested the GLP‑1 analogue liraglutide on obese cats, achieving about a 10% weight loss over two weeks but also observing vomiting, diarrhea and reduced appetite. The study, conducted by the Federal University of Uberlândia, highlights the potential of such medications for pet obesity, while U.S. firm Okava is trialing an exenatide‑releasing implant for overweight cats.

The rise of human GLP‑1 drugs such as Mounjaro and Ozempic has generated a surge in cosmetic‑procedure interest. In Brazil, plastic surgeons report that roughly 39% of users of these medicines consider surgical correction and 41% contemplate non‑surgical aesthetic treatments to address facial laxity, excess skin and volume loss. Terms like “Ozempic Face” and “Mounjaro Makeover” have entered public discourse as patients seek solutions after rapid weight loss.